Elizabeth C Mormino1, Rebecca A Betensky2, Trey Hedden2, Aaron P Schultz2, Andrew Ward2, Willem Huijbers2, Dorene M Rentz2, Keith A Johnson2, Reisa A Sperling2. 1. From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA. bmormino@nmr.mgh.harvard.edu. 2. From the Departments of Neurology (E.C.M., A.P.S., D.M.R., K.A.J., R.A.S.), Radiology (T.H., A.P.S., K.A.J., R.A.S.), and Psychiatry (A.P.S., A.W.), and the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (K.A.J.), Massachusetts General Hospital, Harvard Medical School; the Department of Biostatistics (R.A.B.), Harvard School of Public Health, Boston; the Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology (T.H.), Massachusetts General Hospital, Charleston; and the Center for Alzheimer Research and Treatment, Department of Neurology (A.W., W.H., D.M.R., K.A.J., R.A.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: To examine whether β-amyloid (Aβ) and APOE ε4 status independently contribute or interact to influence longitudinal cognitive decline in clinically normal older individuals (CN). METHODS: Data from 490 CNs were aggregated across 3 observational cohort studies (Harvard Aging Brain Study, Alzheimer's Disease Neuroimaging Initiative, and Australian Imaging Biomarkers and Lifestyle Study of Ageing; median age = 75.0 years, 255 female), and the contributions of APOE ε4 and Aβ on longitudinal change over a median of 1.49 years were examined. Cognitive decline was assessed with the Mini-Mental State Examination (MMSE) and Logical Memory (immediate and delayed recall scores). RESULTS: High Aβ participants were more likely to be APOE ε4+ than low Aβ participants. CNs who were both high Aβ and APOE ε4+ showed greater decline in Logical Memory immediate recall (p < 0.087), Logical Memory delayed recall (p < 0.024), and MMSE (p < 0.034) compared to all other groups (low Aβ/APOE ε4-, low Aβ/APOE ε4+, and high Aβ/APOE ε4-). No other pairwise contrast was significant for any cognitive measure. CONCLUSIONS: Clinically normal individuals who are APOE ε4+ and have high Aβ showed the highest cognitive decline. These results suggest that Aβ and APOE ε4 are not redundant contributors of decline in aging but rather interact to promote decline during the short follow-up period examined in this study. Longer follow-up periods will be essential to fully elucidate the influence of Alzheimer disease risk factors on cognitive decline in aging.
OBJECTIVE: To examine whether β-amyloid (Aβ) and APOE ε4 status independently contribute or interact to influence longitudinal cognitive decline in clinically normal older individuals (CN). METHODS: Data from 490 CNs were aggregated across 3 observational cohort studies (Harvard Aging Brain Study, Alzheimer's Disease Neuroimaging Initiative, and Australian Imaging Biomarkers and Lifestyle Study of Ageing; median age = 75.0 years, 255 female), and the contributions of APOE ε4 and Aβ on longitudinal change over a median of 1.49 years were examined. Cognitive decline was assessed with the Mini-Mental State Examination (MMSE) and Logical Memory (immediate and delayed recall scores). RESULTS: High Aβ participants were more likely to be APOE ε4+ than low Aβ participants. CNs who were both high Aβ and APOE ε4+ showed greater decline in Logical Memory immediate recall (p < 0.087), Logical Memory delayed recall (p < 0.024), and MMSE (p < 0.034) compared to all other groups (low Aβ/APOE ε4-, low Aβ/APOE ε4+, and high Aβ/APOE ε4-). No other pairwise contrast was significant for any cognitive measure. CONCLUSIONS: Clinically normal individuals who are APOE ε4+ and have high Aβ showed the highest cognitive decline. These results suggest that Aβ and APOE ε4 are not redundant contributors of decline in aging but rather interact to promote decline during the short follow-up period examined in this study. Longer follow-up periods will be essential to fully elucidate the influence of Alzheimer disease risk factors on cognitive decline in aging.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe Journal: Ann Neurol Date: 2011-01 Impact factor: 10.422
Authors: E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust Journal: Brain Date: 2008-11-28 Impact factor: 13.501
Authors: K Kantarci; V Lowe; S A Przybelski; S D Weigand; M L Senjem; R J Ivnik; G M Preboske; R Roberts; Y E Geda; B F Boeve; D S Knopman; R C Petersen; C R Jack Journal: Neurology Date: 2011-12-21 Impact factor: 9.910
Authors: Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Yvette I Sheline; John C Morris; Abraham Z Snyder; Joseph L Price; Zhizi Yan; Gina D'Angelo; Collin Liu; Sachin Dixit; Tammie Benzinger; Anne Fagan; Alison Goate; Mark A Mintun Journal: J Neurosci Date: 2010-12-15 Impact factor: 6.167
Authors: Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Andrew B Wolf; Jon Valla; Guojun Bu; Jungsu Kim; Mary Jo LaDu; Eric M Reiman; Richard J Caselli Journal: Alzheimers Res Ther Date: 2013-09-03 Impact factor: 6.982
Authors: Anna Rieckmann; Trey Hedden; Alayna P Younger; Reisa A Sperling; Keith A Johnson; Randy L Buckner Journal: Hum Brain Mapp Date: 2015-11-06 Impact factor: 5.038
Authors: Aaron P Schultz; Reina W Kloet; Hamid R Sohrabi; Louise van der Weerd; Sanneke van Rooden; Marieke J H Wermer; Laure Grand Moursel; Maqsood Yaqub; Bart N M van Berckel; Pratishtha Chatterjee; Samantha L Gardener; Kevin Taddei; Anne M Fagan; Tammie L Benzinger; John C Morris; Reisa Sperling; Keith Johnson; Randall J Bateman; M Edip Gurol; Mark A van Buchem; Ralph Martins; Jasmeer P Chhatwal; Steven M Greenberg Journal: Ann Neurol Date: 2019-08-12 Impact factor: 10.422
Authors: Jennifer S Rabin; Aaron P Schultz; Trey Hedden; Anand Viswanathan; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Rachel F Buckley; Hyun-Sik Yang; Michael Properzi; Vaishnavi Rao; Dylan R Kirn; Kathryn V Papp; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Rebecca E Amariglio; Elizabeth C Mormino; Alison C Pietras; Gad A Marshall; Patrizia Vannini; Keith A Johnson; Reisa A Sperling; Dorene M Rentz Journal: Neurology Date: 2015-06-05 Impact factor: 9.910
Authors: Matthew E Growdon; Aaron P Schultz; Alexander S Dagley; Rebecca E Amariglio; Trey Hedden; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Mark W Albers; Gad A Marshall Journal: Neurology Date: 2015-05-01 Impact factor: 9.910
Authors: Trey Hedden; Aaron P Schultz; Anna Rieckmann; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Randy L Buckner Journal: Cereb Cortex Date: 2014-10-14 Impact factor: 5.357
Authors: Thor D Stein; Philip H Montenigro; Victor E Alvarez; Weiming Xia; John F Crary; Yorghos Tripodis; Daniel H Daneshvar; Jesse Mez; Todd Solomon; Gaoyuan Meng; Caroline A Kubilus; Kerry A Cormier; Steven Meng; Katharine Babcock; Patrick Kiernan; Lauren Murphy; Christopher J Nowinski; Brett Martin; Diane Dixon; Robert A Stern; Robert C Cantu; Neil W Kowall; Ann C McKee Journal: Acta Neuropathol Date: 2015-05-06 Impact factor: 17.088
Authors: Willem Huijbers; Aaron P Schultz; Kathryn V Papp; Molly R LaPoint; Bernard Hanseeuw; Jasmeer P Chhatwal; Trey Hedden; Keith A Johnson; Reisa A Sperling Journal: J Neurosci Date: 2018-11-27 Impact factor: 6.167
Authors: Michael J Properzi; Rachel F Buckley; Jasmeer P Chhatwal; Michael C Donohue; Cristina Lois; Elizabeth C Mormino; Keith A Johnson; Reisa A Sperling; Aaron P Schultz Journal: Neuroimage Date: 2018-11-17 Impact factor: 6.556